CEO Ron Cooper said the company’s focus is advancing its DDX platform, a proprietary non-viral gene therapy technology, with its lead program detalimogene being developed for non-muscle invasive ...
Oncology Media Relations Oncology_media_relations@its.jnj.com Investor contact: Jess Margevich investor-relations@its.jnj.com ...
The use of ketamine has doubled in 10 years, the Office for National Statistics says [/BBC] A 14-year-old pupil has been ...
A 7-year-old child with end-stage kidney failure has successfully avoided dialysis through expert conservative management at Kailash Hospital. Initially diagnosed with Stage 5 Chronic Kidney Disease ...
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare ...
Colorblindness may be doing more than making traffic lights confusing — it could also be hiding a life-threatening warning ...
ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...
Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR ...
Breakthrough solutions aren’t enough. New ideas can’t flourish without “bridgers”—leaders who excel at collaborating across boundaries. by Linda A. Hill, Emily Tedards and Jason Wild Innovation ...
Copyright 2026 The Associated Press. All Rights Reserved. Copyright 2026 The Associated Press. All Rights Reserved. Hungary’s Foreign Minister Peter Szijjarto ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results